The fast-spreading delta form is so contagious that it has highlighted vaccine flaws and altered the outlook for stopping the epidemic, according to Moderna President Stephen Hoge.
In a phone interview, he said Delta is “simply so good at infecting people and multiplying that it increases the bar on how strong vaccinations have to be.” “It has actually shown some of the flaws that vaccines have earlier than you might expect.”
Moderna released a new analysis from its phase three study on Wednesday, showing that breakthrough Covid cases, which occur in fully vaccinated people, were less common in a group of trial participants who had recently been inoculated, implying that the Covid vaccine’s protection wears off over time.
According to the business; 88 breakthrough cases were found out of 11,431 people vaccinated between December and March; compared to 162 breakthrough cases out of 14,746 trial participants inoculated from July to October 2020.
“The delta variant is not an immune escape variant,” he said, adding the variant is simply “weakening our defenses” at a time when vaccine protection is declining.
“It’s what has probably led to the phase three results that we’re seeing right now. It’s led to the difference in the real-world efficacy; that’s been reported between the vaccines this summer,” he said.
Hoge said the drugmaker’s latest results; which haven’t been peer-reviewed yet; builds its case for the wide use of Covid booster shots.
“It’s the reason to get ahead of the problem and boost,” he said.
His remarks came ahead of a meeting of the Food and Drug Administration’s vaccine advisory committee on Friday; when a group of independent experts will debate whether there is enough evidence to approve widespread booster shot distribution across the United States.
The agency’s Vaccines and Related Biological Products Advisory Committee will discuss whether third doses of Pfizer and BioNTech’s vaccine should be administered; as federal health officials said they need more time to study Moderna’s request for further doses.
The outcome of the meeting could have ramifications for Moderna’s booster shot plans in the future.
The scientific community is divided; on whether or not booster shots for the general populace are necessary.
The Biden administration has stated that assuming FDA approval; it plans to begin providing booster shots to the general public as soon as next week. The measure is part of President Joe Biden’s larger strategy to deal with an increase in Covid cases; caused by the fast-spreading delta form.